Limitations of subcloning as a tool to characterize homogeneity of a cell population by Barkhordarian, Hedieh et al.
 Poster Number 1 
LIMITATIONS OF SUBCLONING AS A TOOL TO CHARACTERIZE HOMOGENEITY OF A CELL 
POPULATION 
 
Hedieh Barkhordarian, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
hrahimi@amgen.com 
Tharmala Tharmalingam, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
Nicole Tejeda, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
  Pheng Yam, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
Sam Yaghmour, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
Kristi Daris, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
Fang Lu, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
 Trent Munro, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
 Chetan Goudar, Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
 Jennitte Stevens Cell Line Development, Drug Substance Technologies, Amgen, Inc., USA 
 
 
Cloning, or the derivation of a cell line from a single cell is a critical step in the generation of a manufacturing cell 
line.  The expectation is that the process of cloning will result in a uniform and homogeneous cell line that will 
ensure robust product quality over the lifetime of the product.  Regulatory guidelines require the sponsors 
provide assurance of clonality of the production cell line and when such evidence is not available, additional 
studies are required to further ensure consistent long-term manufacturing of the product.  One approach to 
characterize homogeneity of a cell line is subclone analysis where clones are generated from the original cell 
line and an evaluation of their similarity is performed lines. To study the suitability of subclone analysis to 
provide additional assurance that a production cell line is clonally derived, an antibody producing CHO Master 
Cell Bank (MCB), which was cloned by a validated FACS method and with a clear documented day 0 image 
was characterized. Specifically, this MCB was subcloned and imaged to assure each of the subclones were 
derived from a single cell.  A total of 46 subclones were analyzed for growth, productivity, product quality, as 
well as copy number and integration site analysis.   Despite demonstration of clonality for both the MCB and the 
subclones, significant diversity in cell growth, protein productivity, and product quality attributes was observed 
between the 46 subclones.  The diversity in protein productivity and quality were reproduced across bioreactor 
scales, suggesting that albeit different, the subclones were stable populations that varied from the parental 
clonal cell line.   Additionally, while ~2-fold shifts in copy number were seen, no significant integration site 
changes were observed. Our data suggest subcloning induces changes (genetic or epigenetic) outside the 
region of the transgene which result in the subclones exhibiting a wide diversity in cell growth protein 
productivity, and product quality.   Transcriptomic and genomic characterization studies are underway to further 
characterize the differences between subclones and the MCB.   Importantly, the subclones do keep their 
individual characteristics as they mature and stabilize, suggesting that the resulting population that grows out of 
a single cell is stable but with unique properties. Overall, this work adds to the growing body of work on CHO 
cell plasticity and suggests that subcloning is not an effective approach to demonstrate homogeneity of a cell 
bank. 
 
 
